Home | Welcome to Contract Pharma   
Last Updated Saturday, March 28 2015

Print RSS Feed

Pharma Beat

Related Searches: Development Supplement Clinical Trial API
Adele Graham-King, Contributing Editor
March 6, 2015
Repurposing drug candidates that never saw the light of day  Read More »
Adele Graham-King, Contributing Editor
January 29, 2015
To use or not to use unlicensed drugs? That is the question.  Read More »
Adele Graham-King, Consultant
November 13, 2014
Highly technical solution can easily be interpreted and potentially inexpensive.  Read More »
The End of a Century
Adele Graham-King
October 14, 2014
Looking at 15 years of pharmaceutical evolution.  Read More »
Adele Graham-King
July 21, 2014
A new WHO report raises some frightening questions on antimicrobial resistance, while Scotland’s PharmaSea Project looks for answers in the oceans’ depths  Read More »
Girish Malhotra, EPCOT International
June 3, 2014
Saying “No” to change is normal, but adopting true QbD practices could save the industry about 20-25% of its global revenue and allow pharma to add two to three billion patients to its customer base   Read More »
Girish Malhotra, EPCOT International
May 1, 2014
Will Sun’s latest acquisition, and India’s first peer-to-peer pharma mega-buy, change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?  Read More »
Ed Silverman, Contributing Editor
March 7, 2014
After a rancorous debate that has frayed the seemingly monolithic posture of the pharma industry and raised fundamental issues about transparency, Johnson & Johnson recently struck a noteworthy deal with a group of Yale University researchers to…  Read More »
Ed Silverman, Contributing Editor
January 24, 2014
When is a patent settlement between drug makers a legitimate deal and not the equivalent of a bribe? This is a question that authorities on both sides of the Atlantic Ocean have been trying to answer for the past few years with varying degrees of suc…  Read More »
Ed Silverman, Contributing Editor
November 13, 2013
Can FDA get tough?  Read More »
Ed Silverman, Contributing Editor
October 9, 2013
GSK’s travails in China  Read More »
Ed Silverman , Contributing Editor
September 5, 2013
What’s holding up e-serialization this time?  Read More »
Ed Silverman, Contributing Editor
July 17, 2013
Who gets access?  Read More »
Ed Silverman, Contributing Editor
June 5, 2013
There was a time when Merck was synonymous with innovative medicine. Now, though, the drug maker gets high marks for innovative marketing, but not much more. Consider the recent FDA approval of a new combination cholesterol pill that, instead of offe…  Read More »
Ed Silverman, Contributing Editor
April 3, 2013
SCOTUS to listen to state vs. federal pre-emption case on drug safety  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On